Affimed Stock Price, News & Analysis

Welcome to our dedicated page for Affimed news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed stock.

Affimed N.V. (AFMD) has been a Nasdaq-listed, clinical-stage immuno-oncology company focused on innate cell engagers (ICE®) generated on its proprietary ROCK® platform. Company news has highlighted how these ICE® molecules are being developed to recognize and kill a range of hematologic and solid tumors by engaging innate immune cells.

News coverage for AFMD includes detailed clinical updates on key ICE® programs such as AFM24, AFM28 and acimtamig (AFM13). Releases describe AFM24 as a tetravalent, bispecific ICE® targeting CD16A and EGFR, with data in advanced or metastatic non-small cell lung cancer, including combinations with atezolizumab. For AFM28, Affimed has reported early Phase 1 results in relapsed/refractory acute myeloid leukemia, including composite complete remission rates and safety findings. Additional news has covered acimtamig in combination with AlloNK® (AB-101) in classical Hodgkin lymphoma, with abstracts accepted for major oncology meetings.

Another important category of AFMD news relates to corporate and listing developments. In May 2025, Affimed announced that it had filed for insolvency proceedings in Mannheim, Germany, citing overindebtedness and liquidity concerns. Shortly thereafter, the company disclosed that Nasdaq staff would suspend trading of its common shares and proceed with a delisting process, culminating in a Form 25 filing to remove its common stock from Nasdaq listing and registration.

On this news page, readers can review historical press releases on AFMD’s clinical trial data, conference presentations, investor webcasts, and regulatory and listing updates. For those tracking the company’s ICE® pipeline and its insolvency and delisting process, this archive offers a centralized view of how Affimed’s scientific, clinical, and corporate story has evolved over time.